Objective:

This study aimed to comprehensively investigate the correlation of ERCC1 expression and chemosensitivity of ovarian cancer.

Methods:

The literature on the relationship between the excision repair cross complementary gene 1 (ERCC1) and the chemosensitivity of ovarian cancer published in PubMed, Web of Science, EMBASE, CNKI, and the China Wanfang database from the establishment of the databases to June 2020 were searched. Chemosensitivity is evaluated by clinical effective rate (complete remission plus partial remission). Statistical analysis was carried out by using Stata 15.1 software.

Results:

A total of 11 articles met the inclusion criteria, consisting of 758 patients with ovarian cancer. The results showed a significant difference in chemosensitivity between the low expression group and the high expression group of ERCC1 (odds ratio 4.23; 95% confidence interval 2.96, 6.06; P < 0. 01). The same result was shown in the ethnicity subgroup.

Conclusion:

The chemosensitivity of ovarian cancer patients with a low expression of ERCC1 is better than that of patients with a high expression.

中文翻译：

---

卵巢癌患者的 ERCC1 表达和铂类化疗敏感性：一项荟萃分析

客观的：

本研究旨在全面探讨ERCC1表达与卵巢癌化疗敏感性的相关性。

方法：

检索建库至2020年6月发表在PubMed、Web of Science、EMBASE、CNKI、万方数据库上的切除修复交叉互补基因1（ERCC1）与卵巢癌化疗敏感性关系的文献. 通过临床有效率（完全缓解加部分缓解）评估化学敏感性。使用Stata 15.1软件进行统计分析。

结果：

共有11篇文章符合纳入标准，包括758名卵巢癌患者。结果显示ERCC1低表达组和高表达组的化疗敏感性有显着差异（优势比4.23；95%置信区间2.96、6.06；P <0. 01）。在种族亚组中也显示了相同的结果。

结论：

ERCC1低表达的卵巢癌患者的化疗敏感性优于高表达的患者。